Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology firm focused on innovative one-time curative genetic therapies, announced that its CEO, Keith Gottesdiener, will present a corporate overview at the Guggenheim Healthcare Talks on April 3, 2023, at 3:55 p.m. ET in New York, NY. A live audio webcast will be accessible in the company’s News & Events section at www.primemedicine.com, with a replay available for 30 days post-event. Prime Medicine uses advanced Prime Editing technology aimed at treating a wide range of diseases by precisely correcting genetic mutations.
Prime Medicine, a biotechnology firm, reports significant progress in the fourth quarter and full year of 2022. Key highlights include:
- Successful upsized IPO raising $199 million.
- Nominated PM359 as the first development candidate for treating Chronic Granulomatous Disease (CGD).
- New preclinical data showing effective genetic editing and minimal off-target activity.
- Research & Development expenses totaled $86.7 million for 2022, with a net loss of $121.8 million.
- Cash position improved to $293.9 million as of December 31, 2022.
Prime Medicine anticipates moving forward with IND-enabling studies in 2023 and further development of its Prime Editing platform.